cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bioxcel Therapeutics
17 own
13 watching
Current Price
$2.56
$-0.03
(-1.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
98.65M
52-Week High
52-Week High
29.56000
52-Week Low
52-Week Low
1.91000
Average Volume
Average Volume
0.13M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization98.65M
icon52-Week High29.56000
icon52-Week Low1.91000
iconAverage Volume0.13M
iconDividend Yield--
iconP/E Ratio--
What does the Bioxcel Therapeutics do?
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Read More
How much money does Bioxcel Therapeutics make?
News & Events about Bioxcel Therapeutics.
Business Wire
9 months ago
Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BioXcel Therapeutics, Inc. (BioXcel or...
Business Wire
9 months ago
Law Offices of Howard G. Smith announces an investigation on behalf of BioXcel Therapeutics, Inc. (BioXcel or the Company) (NASDAQ: BTAI) investors concerning the Companys possible violations of...
Globe Newswire
9 months ago
SAN DIEGO, June 29, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether BioXcel Therapeutics (NASDAQ: BTAI), any of its executive officers, or others violated securities laws by misrepresenting or failing to timely disclose ...
PR Newswire
9 months ago
Thinking about buying stock in Lucid Group, Eos Energy Enterprises, Nio, DiaMedica Therapeutics, or BioXcel Therapeutics? Thinking about buying stock in Lucid Group, Eos Energy Enterprises, Nio, DiaMedica Therapeutics, or BioXcel Therapeutics? PR Newswire NEW YORK, June 29, 2023 NEW YORK, June 29...
Stock Options Channel
10 months ago
Investors eyeing a purchase of BioXcel Therapeutics Inc (BTAI) shares, but tentative about paying the going market price of 21.78/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February ...
Frequently Asked Questions
Frequently Asked Questions
What is Bioxcel Therapeutics share price today?
plus_minus_icon
Can Indians buy Bioxcel Therapeutics shares?
plus_minus_icon
How can I buy Bioxcel Therapeutics shares from India?
plus_minus_icon
Can Fractional shares of Bioxcel Therapeutics be purchased?
plus_minus_icon
What are the documents required to start investing in Bioxcel Therapeutics stocks?
plus_minus_icon
What is today’s traded volume of Bioxcel Therapeutics?
plus_minus_icon
What is today’s market capitalisation of Bioxcel Therapeutics?
plus_minus_icon
What is the 52-Week High and Low Range of Bioxcel Therapeutics?
plus_minus_icon
What percentage is Bioxcel Therapeutics down from its 52-Week High?
plus_minus_icon
What percentage is Bioxcel Therapeutics up from its 52-Week Low?
plus_minus_icon
Current Price
$2.56
$-0.03
(-1.16%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$4.28
$-0.40 (-8.55 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$1.61
$-0.02 (-1.23 %)
Nkarta Inc
Nkarta Inc
$7.81
$-0.05 (-0.64 %)
Greenwich LifeSciences Inc
Greenwich LifeSciences Inc
$13.00
$-0.05 (-0.38 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
RELMADA THERAPEUTICS INC
RELMADA THERAPEUTICS INC
$4.28
$-0.40 (-8.55 %)
CUE BIOPHARMA INC
CUE BIOPHARMA INC
$1.61
$-0.02 (-1.23 %)
Nkarta Inc
Nkarta Inc
$7.81
$-0.05 (-0.64 %)
Greenwich LifeSciences Inc
Greenwich LifeSciences Inc
$13.00
$-0.05 (-0.38 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00